Recently, biobehavioral nursing scientists have focused their attention on the search for biomarkers or biological signatures to identify patients at risk for various health problems and poor disease outcomes. In response to the national impetus for biomarker discovery, the measurement of biological fluids and tissues has become increasingly sophisticated. Urine proteomics, in particular, may hold great promise for biobehavioral focused nursing scientists for examination of symptomand syndrome-related research questions. Urine proteins are easily accessible secreted proteins that provide direct and indirect windows into bodily functions. Advances in proteomics and biomarker discovery provide new opportunities to conduct research studies with banked and fresh urine to benefit diagnosis, prognosis, and evaluation of outcomes in various disease populations.
For the past three decades, biobehavioral nursing scientists have focused their attention on the search for biomarkers, or biological signatures, to identify patients at risk for health problems and poor disease outcomes (Lovejoy, Thomas, Halliburton, & Mimnaugh, 1987; Thompson & Voss, 2009 ). More recently, this search has led to exploration of molecular biomarkers that can potentially predict patient responses to interventions and therapies. For example, a number of nursing scientists have utilized targeted genetic analysis to predict disease risk as well as to understand patient and family member's responses to genetic risk factors (McQuirter, Castiglia, Loiselle, & Wong, 2010; Metcalfe et al., 2010) .
A biomarker is a measure of a normal biological process, a pathological process, or the response of the body to a therapy. In addition, a biomarker can be used to objectively identify a patient group or subgroup with a disorder, define a treatmentresponsive population, and/or provide a target for future intervention studies. A specific marker may also offer information about the mechanism of action of a drug or therapy, its efficacy, its safety, and its metabolic profile. In response to funding agency requests for studies examining biomarkers, investigators have become increasingly sophisticated in the techniques they use for measurement of biological fluids and tissues. Building on the work of interdisciplinary colleagues, biobehavioral nursing scientists have further expanded their research from the use of system measures, for example, heart rate and blood pressure, to embrace newer technologies to understand symptom experiences Mitchell et al., 2008) as well as recovery from major adverse events (e.g., stroke/depression [Kohen et al., 2008] and traumatic brain injury [Chuang, 2010] ).
One biomarker discovery approach that may hold promise for biobehavioral focused scientists is the examination of the proteome (proteomics). The term proteomics refers to the global analysis of cellular proteins with mass spectrometry (MS)based techniques, image analysis, reverse-phase protein array, amino acid sequencing, and/or bio-informatics to identify and quantify a large number of proteins. Proteomics is focused on cellular or secreted proteins in terms of both their structure and the functional interaction among proteins. Proteomic science uses both qualitative and quantitative comparison of proteomes to explore further biological function (Breedlove & Busenhart, 2005) . In an early review of genomics and proteomics, Kasper (2007) noted that the study of proteomics increased markedly following the completion of the Human Genome Project in 2003. Advances in high-throughput genomics and proteomics have increased the potential for new biomarkers, yet the actual output is still quite limited, with most work to date focusing on cancer detection. Furthermore, the use of proteomics in biobehavioral science development remains virtually unexplored.
The purposes of this review are to (a) present a brief overview of proteomics including measurement issues, (b) provide a rationale for utilizing urine proteomics in biobehavioral research, and (c) use a case study to exemplify some of the methodological challenges involved in data collection and sample preparation.
Proteomics

Proteomics in Biomedical Research
Protein levels and the interrelationships among proteins are influenced by a variety of factors including diet, hormone status, and physical activity, as well as disease state and medication history. It is well established that alterations (i.e., upregulation and downregulation) of protein quantity occur in response to a number of disease processes including cancer and inflammation (Apweiler et al., 2009; Decramer et al., 2008) . With improved analytical approaches for qualitative and quantitative measurement, investigators are increasingly testing proteins as potential biomarkers for gastrointestinal, renal, liver, prostate, and breast cancer (Carey, 2010; Chua, Moore, Charles, & Clarke, 2009; Hoshida et al., 2010; Pejcic, Stojnev, & Stefanovic, 2010) .
The use of body fluids for protein and peptide determination continues to evolve (Schmidt & Aebersold, 2006) . Prior to the advent of the proteomics era, investigators studied proteins in biological fluids using enzyme activity experiments, antibody detection, and microsequencing technology (Klugman, Madhi, & Albrich, 2008; Kopetzki, Lehnert, & Buckel, 1994; Mir, Homs, & Samitier, 2009 ). However, many of these approaches were laborious and ultimately inefficient. The development of MS and enzyme-linked immunosorbent assay (ELISA) technologies combined with a variety of sample and protein preparation strategies increased investigators' ability to quantify even low-abundance proteins in body fluids, including blood, cerebrospinal fluid, and urine. Although these methods and measures have become more accessible and feasible, it still remains to be determined how scientists will utilize proteomics in their protocols to answer questions focused on the biology of symptom reports. Recently, Schmidt, Claassen, and Aebersold (2009) suggested that researchers take a more hypothesisdriven approach to utilizing MS and related technologies.
Proteomics has achieved expansive growth in recent years and is still rapidly growing, fueled by innovative experimental approaches, improvements in sensitivity, resolution, and accuracy of mass analyzers. However, the type and level of proteins in body fluids including blood, urine, and cerebrospinal fluid may not necessarily reflect changes occurring in a particular body system (e.g., heart, lungs, and brain) or coincide with a clinical phenotype (fatigue, dyspnea, and cognitive dysfunction). As Simpson, Whetton, and Diver (2009) note, for proteins to be viable as biomarkers they must have high sensitivity (be positive for those with the disease or disorder) and high specificity (negative for those without the disease or disorder).
The science of determining whether protein levels are sensitive to pharmacologic and nonpharmacologic therapies, which would allow them to be used as outcome measures, is in its infancy. In a recent paper, Pitteri and colleagues (2009) described the use of serum proteomics in the Women's Health Initiative Study to examine outcomes in women treated with estrogen plus progesterone and women treated with estrogen alone. Serum proteins involved in metabolic pathways related to coagulation, metabolism, osteogenesis, inflammation, and blood pressure regulation were upregulated in response to estrogen and estrogen plus progesterone therapy. Such findings open the door for further mechanistic and therapeutic studies utilizing proteomic approaches.
Protein Identification by MS
A proteome reflects not the entire genome of possible open reading frames present in each cell, but rather only those proteins expressed by a cell in a given environment or state. Quantitative proteomics is defined as comparison of relative changes in different proteomes (e.g., disease vs. normal), and it is an important component in the emerging proteomic sciences. Qualitative proteomics refers to the discrimination of the proteome (protein identification) based on its MS characteristics.
Two methods can be employed to generate qualitative and quantitative profiles of complex protein mixtures. The first and more traditionally used is a combination of one-or twodimensional gel electrophoresis (1-DE or 2-DE) with MS. These methods, 1-DE-MS or 2-DE-MS, utilize protein ''spot'' intensities on gels. Using a 2-DE fluorescence system, it is possible to separate up to three different samples within the same 2-D gel. With this approach, an internal standard is present in every gel and thus the gel is normalized to a given internal control. Since the proteins from the different sample types (e.g., healthy/diseased, infected/noninfected) are run on the same gel, they can be directly compared. While resolving power of 2DE-MS is arguably its best feature, it is limited by loading capacity problems that ultimately affect sensitivity. The second method is a more recently developed technique called shotgun proteomics (Goo & Goodlett, 2010) . There are multiple variations on the shotgun proteomic theme (Gilmore & Washburn, 2010) . Many of these approaches involve protease digestion of a complex protein sample to make peptides that are in turn analyzed by tandem mass spectrometry (MS/MS) to identify the proteins from which they were derived. This peptidebased approach circumvents the fundamental decrease in fragmentation efficiency that accompanies increasing molecular weight of proteins. One important limitation of standard shotgun methods is the requisite proteolysis of proteins to peptides, of which only some are detected in the mass spectrometer while many others are not. This loss of protein sequence information means that shotgun proteomic experiments typically produce low protein sequence coverage.
Protein Quantification by MS
A few popular methods of proteomic quantification used in current research include, first, the aforementioned combination of gel electrophoresis and MS. In this approach, 1-DE or 2-DE are used to distinguish differentially expressed proteins based on staining intensity of the gels and proteins identified by tandem MS (MS/MS). Protein identification may also be carried out via simple matrix-assisted laser desorption/ionization-time of flight MS (MALDI-TOF MS) peptide mass fingerprinting. Second, stable-isotope labeling is routinely used in protein quantification. This method introduces pairs of chemically, metabolically, or enzymatically identical ''mass'' tags that may be separated and then corresponding proteins may be identified by MS/MS of the labeled peptides. Third, label-free quantification is a method in which protein quantity is inferred from the number of spectra produced for all peptides from a given protein. This approach has recently become popular for its ease of use.
Currently, large-scale MS assays are expensive and may be beyond the reach of researchers who pose exploratory questions related to symptom candidate biomarkers. However, several multidimensional strategies for protein isolation have been developed that, when combined with MS, can potentially provide a streamlined approach (Adachi, Kumar, Zhang, Olsen, & Mann, 2006; Goo & Goodlett, 2010) . Such methodologies were designed to enrich, fractionate, and quantitate proteins for MS analysis and ultimately biomarker discovery.
Proteomics Data Processing
As pointed out by Founds (2009) in a recent review of systems biology, proteomic analyses, much like genomic analyses, yield massive volumes of data. As such, computational and pathway modeling programs are critical for data analysis and interpretation. In a typical Trans-Proteomic Pipeline (www.systemsbiology.org), the investigator searches acquired MS/MS for protein identification against a database (i.e., International Protein Index [IPI] human protein database) using SEQUEST (Goo & Goodlett, 2010) . Analytical programs such as PeptideProphet and ProteinProphet, which compute the probability of each identification being correct, are used for statistical analysis. Only proteins identified by more than one unique peptide sequence are typically used in the data analysis.
Verification of Proteomic Data
The potential for false positive results with MS requires verification. Initially, proteins of interest identified by MS can be further verified by an orthogonal method such as Western blot analysis followed by a large-scale verification using ELISA if an antibody or an ELISA kit is available. Though investigators have identified many potentially promising biomarker candidates in human disease research with the help of proteomics in recent years, most of the studies have been limited to the discovery stage with putative biomarkers still awaiting verification or already having failed confirmation as true markers when subjected to larger follow-up studies. These results demonstrate the relative ease of putative biomarker discovery coupled to difficulties in validation in current research (Goo & Goodlett, 2010) .
Urine Proteomics Urine as a Biological Fluid for Biomedical Research
Clinical researchers have long been interested in measures, including biomarkers, that can be collected noninvasively, with minimal discomfort and subject burden. At the same time, such measures need to represent the biological mechanism or phenomenon of interest. Researchers view urine collection is viewed as one potential route for noninvasive sample collection. Multiple investigators have utilized urine samples to measure steroid hormones such as cortisol (Heitkemper et al., 1996; Hu, Jiang, Zeng, Chen, & Zhang, 2010; James, Gastrich, Valdimarsdottir, & Bovberg, 2008) , ovarian hormones (Woods & Mitchell et al., 2010) , and peptides such as melatonin (Hu et al., 2010; Thomas, 2009 ).
Because of its accessibility and ease of collection, urine has become one of the more attractive biofluids for proteomics (Goo & Goodlett, 2010; Julian et al., 2009) . Urine is rich in a variety of proteins that are either filtered or secreted into or shed by the urinary tract. Although urine contains fewer proteins than plasma, the urine proteome is complex and variable. Currently, a urine biomarker network links genomic profiles from 127 diseases to 577 proteins detectable in urine (Dudley & Butte, 2009 ). The majority (>80%) of these putative protein biomarkers are linked to multiple as opposed to single disease conditions. This observation is in agreement with the recent development in clinical research noting that a disease phenotype can be better stratified by a panel of biomarkers rather than by a single biomarker.
Urine proteomics were originally thought to be a venue for biomarker discovery solely for renal or uroepithelium disorders. More recent investigations have examined their potential for providing insights into the mechanisms of health problems such as cancer and inflammation that originate outside the urinary tract system (Sobhani, 2010) . Emerging data suggest that disorders involving infection, structure alterations, and coagulopathy are reflected by proteomic alterations in urine.
Similar to serum proteomics, urine proteomics may provide clues to disease etiology and pathophysiologic mechanisms as well as responses to therapeutic interventions. For example, in a clinical study, Buhimschi and colleagues (2008) reported that they had used urine proteomic approaches to successfully predict preeclampsia. Women who developed preeclampsia displayed abnormal urinary profiles more than 10 weeks before clinical manifestation appeared. Using tandem MS/MS and de novo sequencing they identified the biomarkers as nonrandom cleavage products of SERPINA1 and albumin. The 21 amino acid C-terminus fragment of SERPINA1 was highly associated with the presence of severe preeclampsia. The investigators concluded that urine proteomics identified a proteomic fingerprint (group of proteins) that could be potentially useful in the screening for preeclampsia. In addition, they found this approach could distinguish preeclampsia from other hypertensive proteinuric diseases.
Urine proteomic markers have correlated also with coronary artery disease (Zimmerli et al., 2008) , cancer identification (Kentsis, 2010) , and increased risk for organ transplant rejection (Sigdel & Sarwal, 2008) . For example, Snow, Gozal, Valdes, and Jortani (2010) employed 2D fluorescence difference gel electrophoresis (2D DIGE) and MS urine proteomics followed by validation with Western blot using samples from 60 children with obstructive sleep apnea (OSA). They identified 16 differentially expressed proteins in the urine from children with OSA and verified 7 of these proteins by immunoblot analysis. In particular, they found urine uromodulin, urocortin-3, orosomucoid-1, and kallikrein levels to be predictive of OSA. Whether these proteins are linked directly with OSA or represent a more generalized inflammatory response is an intriguing question. It should be noted that, thus far, prospective disease-specific protein biomarkers have been found in only a small subset of the urine proteomes.
Methodological Challenges in Urine Sample Collection
There are a number of methodological challenges involved in the collection of urine samples for proteomic examination. The first challenge is the limited information available on what constitutes the normal urine proteome and variability among normal urine samples. Investigators have identified more than 1,500 proteins in normal/healthy human urine to date (Adachi et al., 2006) . As with serum proteomics, there are established reference profiles of urine proteins (Jia, 2009) . Researchers are just beginning to understand how endogenous variables, for example, urine composition, pH, ion concentrations, as well as peptides and other proteins within the urine, itself, can influence protein levels.
Uromodulin is the most abundant and best characterized protein in the urine of healthy people. It binds several lowmolecular-weight proteins and plasma peptides that enter the tubular filtrate. Uromodulin levels are viewed as a potential biomarker for urinary tract cancers that involve uroepithelial tissues. However, exercise, variations in diet, and circadian rhythms all influence uromodulin levels, indicating that investigators must carefully consider standard operating procedures for urine collection in urine proteomic studies (Afkarian et al., 2010) . For example, should first void urines be used or only 24-hour sample collections? Should physical activity be limited? Should all samples be collected from participants who have fasted or from those who have maintained a constant dietary intake?
Unique to the use of urine as a biofluid is the additional question of standardization across samples. The concentration of a given protein in urine depends on the glomerular filtration rate (Waikar, Sabbisetti, & Bonventre, 2010) . However, investigators may account for this issue in urine proteomics by expressing protein values as per mg of creatinine. Another approach is to normalize the samples with a wellcharacterized urine polypeptide specific to the disease or condition (e.g., creatinine for prostate cancer [Christensen, Evans, Menard, Pintille, & Bristow, 2008] or uromodulin for OSA [Snow et al., 2010] ).
Urine Proteomics in Symptom Research
Although observations support the use of proteomics in investigations that go beyond a single disease to include those examining disorders that share common metabolic pathways, it is unclear whether urine proteomics can be used to identify biomarkers for functional disorders or symptoms. Potential urine proteomic markers that could be linked to symptoms such as fatigue, insomnia, and pain include proteins involved in the production and secretion of inflammatory modulators (e.g., cytokines) thought to play a role in these symptom expressions (Haack, Sanchez, & Mullington, 2007) .
Case Report: Abdominal Pain Exemplar Irritable Bowel Syndrome (IBS)
In 2009, our interdisciplinary team received American Recovery and Reinvestment Act (ARRA) funding for a study entitled ''Pathways to Abdominal Pain in Irritable Bowel Syndrome'' (5RC2NR011959). IBS is a chronic functional gastrointestinal (GI) disorder characterized by abdominal pain associated with alterations in bowel function (constipation, diarrhea). The severity of symptoms ranges from mild to severe and disabling. Current theories of IBS etiology suggest inflammatory as well as visceral sensory disturbances (Drossman, Camilleri, Mayer, & Whitehead, 2002) . There is no known single biomarker that is presently predictive or diagnostic for IBS. Given the heterogeneity of the symptoms (pain, constipation, diarrhea), it is likely that multiple pathophysiologic factors may be at play. The lack of a biomarker that can be used to identify patients with IBS or those who are at risk (e.g., post gastroenteritis) may contribute to the relatively large number of diagnostic procedures performed in these cases as well as the clinical burden of this common condition (Halpert, 2010) .
To date, investigators have not used proteomic methods in human IBS studies. Using an animal model of IBS (abdominal withdrawal reflex in response to bowel distention), Ding and colleagues (2010) examined colonic tissue proteomics. Of the 13 differentially expressed proteins they found, 8 were upregulated and 5 were downregulated in tissues from the IBS rats as compared to non-IBS rats. The authors noted that all of the differentially expressed proteins were associated with inflammation and nerve regulation. Whether the expression patterns can be found with a noninvasive sample (urine) in humans remains to be determined.
The focus of our project was to examine previously collected urine specimens from adult women for specific proteins that could potentially distinguish subgroups of patients with IBS as well as to provide insights into the pathophysiology of increased visceral pain. Thus, our hypothesis was that urine proteomic approaches could be employed to identify biomarker signatures for outcomes of clinical trials as well as to shed light on mechanisms involved in this complex disorder.
Urine Sample Processing and IBS Symptom Clustering
Urine samples had been previously collected as part of a study (NR04142; Jarrett et al., 2009 ) of adult women with and without IBS. Women provided a first morning voided specimen at multiple, predetermined time points. Menstrual cycle phase was accounted for with the use a daily symptom diary for 28 days. The University Human Subjects Review Committee approved the proteomic analysis of stored samples. Subject recruitment and study design were previously described .
To explore the feasibility of conducting proteomic analysis on stored urine samples, our first task was to determine if proteins were intact without degradation in the samples, which had been kept at À80 C for a variable number of years. Preliminary analyses comparing protein quantities of two fresh urine samples to those of stored samples indicated no significant qualitative differences in number of proteins identified.
The next step was to determine the specific samples we would pool for this feasibility shotgun study of the urine proteome. For the purposes of this project, we classified IBS subjects based on symptom profiles derived from both a prospective 28-day diary and recall-questionnaire data. In particular, we used data derived from measures of abdominal pain, constipation, diarrhea, and psychological distress. In the daily diary, women reported GI and psychological distress symptoms on a scale of 0 (not present) to 4 (severe) as previously described . Based on the natural clustering of symptoms, we selected four symptom groups: (a) constipation (n ¼ 19), (b) diarrhea þ high pain (n ¼ 13), (c) diarrhea þ low pain (n ¼ 19), and (d) high pain þ high psychological (n ¼ 12) distress. This symptom classification matched our earlier work in which we described IBS bowel pattern subgroup (diarrhea and constipation) differences in heart rate variability (Jarrett et al., 2008) and stress hormone level (cortisol and catecholamine), especially during sleep (Burr, Jarrett, Cain, Jun, & Heitkemper, 2009) . A fifth group (controls, n ¼ 10) comprised women who did not have a history of IBS and reported no or low GI symptom frequency in their daily diaries.
Using self-report (daily diary) of symptoms and menstrual flow, we screened individual-subject samples for menstrual cycle phase to avoid assaying samples collected during menses. In addition, we tested all samples for hemoglobin (presence of red blood cells [RBCs]) and excluded samples from the analysis if we found hemoglobin levels greater than 0.03 mgdL. Of the 103 urine samples we tested, 7 were positive for hemoglobin. Of the 96 remaining samples without the presence of blood, we used 50 for proteomics study. In each group, we collected 3 mL of urine from 10 subjects to make a 30 mL total pooled sample ( Figure 1) . Investigators, including the operator of the MS, were blinded to the match between the symptom subgroup and sample until we completed MS analyses.
Proteomic Analysis of IBS Urine Samples
We performed MS to qualitatively and quantitatively catalog proteins in the pooled samples. We analyzed peptide digestion products by electrospray ionization on a linear ion trap Velos mass spectrometer (Thermo Scientific Corp., San Jose, CA). For each liquid chromatography-tandem MS (LC-MS/MS), we loaded approximately 0.5 μg of peptides on the column and eluted the peptides in acetonitrile gradient. To maximize protein identification without protein fractionation, we employed the data-independent PAcIFIC (Panchaud et al., 2009 ) method, which acquires data every 37.5 m/z units. We performed each experiment in duplicate (Figure 1) .
We identified more than 800 proteins by MS of urine from each IBS subgroup. Of these more than 200 proteins showed +2-fold differences in protein quantity compared to the normal control group.
We based our selection of the initial candidate proteins for verification on the current hypothesized models (e.g., heightened pain sensitivity and inflammation) of IBS pathophysiology as well as the good agreement between the two replicate MS datasets. To select proteins for follow-up verification study with Western blot, we considered the potential risk for the protein to serve as a biomarker in IBS. In our initial examination, we found the protein gelsolin was upregulated in both the diarrhea þ high pain and high pain þ high psychological distress subgroups as compared to the control sample, possibly representing a pain biomarker for IBS ( Figure 2A ). Gelsolin is an actin regulator and an inhibitor of apoptosis. In this latter role, it appears to stabilize mitochondrial membranes. We next verified the pooled MS findings using Western blot analysis to determine if we could replicate group differences in gelsolin levels ( Figure 2B) .
Looking ahead, the next step will be verifying the expression level of gelsolin as well as other proteins in the urine from individual IBS and control subjects that make up the pooled sample by using ELISA. Ultimately, these results will need to be verified in a larger cohort. However, transition to these steps is dependent in part on the availability of suitable antibodies. In some cases, an antibody is not adequately specific to differentiate different isoforms of the protein.
We should point out that one of the limitations of this feasibility study was that we did not consistently randomize individual samples from a subgroup sample because one subgroup only contained 10 subjects who met the clinical phenotype criteria. In addition, at this point, we can only speculate as to the potential role of gelsolin in pathways responsible for pain sensitivity. To date, investigators have noted that the levels are altered in the plasma and cerebrospinal fluid of patients who are HIVþ, suggesting a role in inflammation (Pottiez, Haverland, & Ciborowski, 2010) .
Future Directions
Proteomics is a rapidly growing field with the potential for advancing nursing research. It remains to be determined, however, whether urine proteomics will yield useful biomarkers for clinical and mechanistic studies of chronic disorders such as IBS. In order for urine proteomic measures to be viewed as biomarkers, it is critical that the values represent an established scientific framework or body of evidence that elucidates the physiological, toxicologic, pharmacologic, or clinical significance of the test results. Its utility as an approach to biomarker discovery will be closely linked to how clinical researchers can use it to predict symptom occurrence and response to therapies. Sufficiently trained nursing scientists and well-established collaborations between proteomic core facilities and individual investigators are the cornerstones to integrate proteomics approaches into the research repertoire of nursing scientists. Figure 1 . Schematic presentation of proteomics sample preparation and mass spectrometry (MS) workflow. For each group, we collected 30 ml of urine by pooling 3 ml of urine from 10 subjects. We included only first morning void samples and those not containing blood in the study. We centrifuged the pooled samples briefly to remove cell debris and impurities and then concentrated them by reducing volume using a 3-kDa cutoff filter. We isolated and purified urine protein by trichloroacetic acid precipitation and then subjected it to trypsinization for MS. We acquired MS data in duplicate and carried out quantification by spectral counting. We validated MS quantification either by Western blot or ELISA analyses. Figure 2 . Expression levels of gelsolin (GSN) in four irritable bowel syndrome (IBS) subgroups and the control group. A. We used spectral counts from the mass spectrometry analysis to represent fold changes in IBS subgroups in comparison to the control group. B. We measured protein expression level by Western blot using a specific antibody to GSN. The sample order is the same as in A.
